骨髓瘤演变与结局中的免疫改变:路在何方?
本文综述多发性骨髓瘤(MM)及其前驱意义未明单克隆丙种球蛋白病(MGUS)与免疫衰老的关联,指出慢性B/浆细胞活化可能参与MGUS起源,仅1%的MGUS个体每年进展为MM,免疫系统可特异性识别MGUS病变,临床前模型提供固有与适应性免疫监视证据。MM伴肿瘤生长模式和区域免疫原位调节的空间改变,肿瘤与微环境因素共同导致免疫麻痹,促进克隆浆细胞播散并增加感染风险。免疫特征异质性与免疫治疗(包括T细胞重定向)后结局相关,需进一步研究系统性免疫改变对体内免疫功能的影响,并将免疫生物标志物前瞻性整合入风险模型。
要点
- MGUS在老年人中常见,仅1%的MGUS个体每年进展为MM。
- 临床前MM模型提供固有与适应性免疫监视证据,免疫系统可特异性识别MGUS病变。
- 肿瘤与微环境因素共同导致免疫麻痹,促进克隆浆细胞播散并增加MM患者感染风险。
核心结论
- 理解系统性免疫改变如何影响体内自然或合成肿瘤/抗原特异性免疫的功能与持久性需进一步研究。
- 保持或恢复免疫功能可能对预防临床MM和治疗活动性疾病时的长期结局至关重要。
- 需对免疫生物标志物进行基准化并前瞻性整合入当前风险模型,同时加深对体内肿瘤免疫机制的理解,以优化免疫策略并改善MM结局。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- MGUS在老年人中常见,仅1%的MGUS个体每年进展为MM。
- 免疫系统可特异性识别MGUS病变,临床前MM模型提供固有与适应性免疫监视证据。
- 多组学研究已识别MGUS阶段的若干系统性改变,提示演变为临床恶性肿瘤前免疫衰老加速。
- MM与肿瘤生长模式和区域免疫原位调节的空间改变相关。
- 肿瘤与微环境相关因素共同导致免疫麻痹,促进克隆浆细胞播散并增加MM患者感染风险。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The pathogenesis of multiple myeloma (MM) and its precursor monoclonal gammopathy of undetermined significance (MGUS) is linked to an aging immune system. Chronic activation of B/plasma cells may contribute to the origin of MGUS, which is frequent in the older individuals. However, only 1% of individuals with MGUS annually experience progression to MM. The immune system can specifically recognize MGUS lesions, and preclinical MM models provide evidence for both innate and adaptive immune surveillance. Multiomic studies have identified several systemic alterations at the MGUS stage, suggesting accelerated immune aging prior to evolution into clinical malignancy. MM is further associated with spatial alterations in patterns of tumor growth and in situ regulation of regional immunity. Both tumor and microenvironment-related factors contribute to immune paresis, which facilitates the dissemination of clonal plasma cells, and increases the risk of infections in patients with MM. Immune profiles in blood or marrow exhibit considerable heterogeneity, and have been linked to outcomes following immune therapies, including T-cell redirection. Understanding how underlying systemic immune changes impact in vivo function and durability of natural or synthetic tumor/antigen-specific immunity needs further study. Preserving or restoring immune function may be critical for long-term outcomes both in the context of prevention of clinical MM and of treating active disease. Benchmarking of immune biomarkers followed by its prospective integration into current risk models, together with improved understanding of mechanisms underlying tumor immunity in vivo, are needed to optimize immune approaches and improve outcomes in MM.
引用
- Dhodapkar MV, Paiva B. Immune alterations in myeloma evolution and outcomes: quo vadis? Blood. 2025. PMID: 40623045. doi:10.1182/blood.2024026227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。